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Abstract
In this contribution, several opportunities and challenges for long axial field of view (LAFOV) PET are described. It is an 
anthology in which the main issues have been highlighted. A consolidated overview of the camera system implementation, 
business and financial plan, opportunities and challenges is provided. What the nuclear medicine and molecular imaging 
community can expect from these new PET/CT scanners is the delivery of more comprehensive information to the clinicians 
for advancing diagnosis, therapy evaluation and clinical research.
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Introduction
After its commercial introduction in 1978 [1], positron emis-
sion tomography (PET) was primarily used as an advanced 
in vivo imaging technique to measure regional physiology 
non-invasively, with an initial focus on pathophysiological 
studies of the brain [2]. One of the first widespread clinical 
applications was the assessment of myocardial viability [3]. 
It was not until the mid-1990s, however, before PET really 
entered the clinical domain [4]. The development of whole-
body PET acquisitions made it possible to survey the entire 
body [5]. Using this technique, it was subsequently shown 
that  [18F]FDG (whole-body) PET was the most sensitive 
method for detecting metastases, which led to its acceptance 
as a landmark clinical diagnostic tool in oncology [6, 7].
Using a conventional PET scanner, a whole-body scan is 
acquired by moving the patient bed through the gantry. This 
is needed because of the limited axial field of view (FOV) 
of 15 to 25 cm of conventional scanners. Although sensitiv-
ity has steadily increased over the years and, more recently, 
with the introduction of digital PET systems [8], at present, 
the typical duration of a conventional whole-body PET/CT 
scan, as available in the majority of imaging institutes, is 
still relatively long (i.e. 10–30 min) in order to acquire suf-
ficient counts for the entire body. A limitation of whole-body 
imaging (essentially a series of successive static scans) is 
that it renders the acquisition of dynamic scans less practical 
and, consequently in a clinical setting, images usually are 
analysed qualitatively (e.g. visually) or semi-quantitatively 
(e.g. standardised uptake value (SUV) or tumour-to-blood 
ratios (TBR)) [9].
For  [18F]FDG, the most common tracer used in clinical 
practice, semi-quantitative SUV analysis is an acceptable 
approach, as there is generally a good correlation between 
SUV and glucose metabolism derived from dynamic PET 
scans. When used for response monitoring purposes, how-
ever, one should be aware of a possible dissociation between 
these parameters, e.g. due to a change in plasma clearance 
that is not accounted for in the SUV calculation [10]. For 
most other tracers, however, the relationship between SUV 
and the underlying biological parameter of interest is less 
clear. This is due to the fact that SUV does not only repre-
sent the biological parameter of interest, but also contains 
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free and non-specific signals. These contributions to the 
overall (SUV) signal can be so large that any differences 
in the specific biological signal may be lost. A clear exam-
ple is given by  [11C]erlotinib, where both SUV and TBR, 
derived from static scans, do not show significant differences 
between tumours with and tumours without mutated epider-
mal growth factor receptors (EGFR), in contrast to the vol-
ume of distribution (VT) derived from dynamic scans [11].
Although PET has the potential to become an important 
non-invasive (whole-body) tool in precision medicine, the 
 [11C]erlotinib example illustrates a current dilemma. In 
principle, PET could be used to predict response to therapy, 
as higher  [11C]erlotinib uptake in lesions indicates bet-
ter response to erlotinib therapy. For a single lesion, this 
could be achieved using VT derived from a dynamic scan. 
Although, in theory, it is possible to perform a dynamic scan 
by acquiring multiple single bed acquisitions repeatedly or, 
more recently, using a continuously moving bed acquisition 
protocol, the temporal resolution of such an approach is only 
sufficient for some selected applications with slow kinetics 
(such as Patlak analysis of  [18F]DG uptake). In the majority 
of cases, however, kinetic analysis requires higher temporal 
resolution that can only be achieved by dynamic scanning 
of a predefined single bed position. As overall response will 
depend on the “poorest” lesion, it is possible that this lesion 
will be missed. To assess all lesions, a whole-body scan 
would be required, but this means the acquisition of static 
scans for successive bed positions and, at least for  [11C]erlo-
tinib, such scans are non-informative [12].
The  [11C]erlotinib example is not unique. It applies to 
most tracers where the (specific) signal of interest is only 
part of the total PET signal. The dilemma whether to per-
form a (static) whole-body scan, covering all lesions, or an 
accurate dynamic scan over a more limited axial FOV can 
be resolved with the newest generation of PET/CT scan-
ners, a so-called long axial field of view (LAFOV) PET [13]. 
Although the term total-body PET has been used for such 
a scanner, strictly speaking, this is only correct for systems 
with an axial FOV of at least 2 m. To be more general, the 
term LAFOV PET seems more appropriate, indicating any 
scanner with a significantly extended axial FOV (longer than 
1 m), enabling dynamic acquisitions of all (body) lesions 
simultaneously. In addition, according to NASA’s anthro-
pometric dimensional data, the torso and head of 95% of the 
USA male population will be within the axial field of view 
of a 1-m-long PET scanner, therefore providing simultane-
ous coverage of all major internal organs [14].
An important additional advantage of a LAFOV PET 
is the substantial increase in sensitivity (a factor of 10 to 
40 depending on the volume of detector material, i.e. the 
actual length of the scanner) compared with a conventional 
PET scanner [15]. This, in turn, allows for faster scans (e.g. 
higher patient throughput) and/or an appreciable reduction 
in injected dose [16], leading to new clinical indications, 
patient populations, and research possibilities [17]. This arti-
cle describes the opportunities LAFOV PET systems offer, 
together with what is needed for installation in a univer-
sity medical centre (i.e. clinical support, business plan and 
change of infrastructure) and new challenges that need to be 
addressed in order to make optimal use of this new system.
New clinical and research applications
High patient throughput
As mentioned above, the higher sensitivity provides an 
opportunity for faster acquisitions and thus allows for scan-
ning more patients within the same time frame. In terms of 
patient throughput, it may be possible to scan as many as 6–8 
patients per hour, provided that patient setup can be stream-
lined. As tracer production corresponds to a substantial part 
of overall costs, this could lead to an important reduction in 
scanning costs (i.e. more patients can be scanned with the 
same tracer batch). Furthermore, a reduction in acquisition 
time may make it easier for patients who are less mobile (e.g. 
intensive care patients), who normally need sedation (e.g. 
claustrophobic or extremely nervous patients and children) 
or who are in a lot of pain (e.g. oncology patients).
High‑risk population screening
Alternatively, the higher sensitivity may be used to lower the 
injected dose, which in turn will result in a lower radiation 
burden for the patient. It may even be possible to reduce 
the injected dose to such an extent that LAFOV PET/CT 
could be used for screening. This may be very relevant for 
high-risk populations of any disease in which early detection 
may substantially increase the potential of successful treat-
ment. For example, conventional PET/CT when combined 
with blood testing has emerged as a potential screening tool 
for early cancer diagnosis and guided interventions [18]. 
Likewise, targeted screening for prospective patients with 
dementia, where pathological amyloid depositions in the 
brain may accumulate 10 to 20 years before manifestation 
of the first symptoms [19] or cardiovascular diseases may 
lead to increased treatment efficacy and a prolonged high 
quality of life.
Paediatric imaging
The possibility of reducing radiation dose is also helpful 
when scanning children, whose cells are more sensitive to 
radiation damage. Paediatric patients are frequently diag-
nosed with malignant diseases that are characterised by a 
diffuse pattern of involvement. For example, haematological 
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malignancies, such as lymphomas and leukaemia, which 
involve both bone marrow and associated organs (e.g., 
lymph nodes and spleen) [20], account for a large proportion 
of paediatric cancers. Apart from reducing injected dose, the 
faster scanning option of a LAFOV PET/CT may also be 
useful in children, as it can help reduce motion artefacts and 
it may limit the need for anaesthesia, which is a substantial 
additional obstacle for performing repeated PET/CT scans 
during a course of treatment.
Drug development
As mentioned earlier, PET has potential as a non-invasive 
tool in precision medicine. Similarly, PET may facilitate and 
improve efficacy of the drug development process, a process 
that is known to be highly inefficient and expensive [21]. 
At present, however, a major limitation is the maximum 
radiation dose permissible, which often limits the number 
of scans that can be performed during a trial, especially in 
volunteers. The lower doses that are possible with a LAFOV 
PET/CT scanner also means that there are less restrictions 
in the number of scans, which provides more flexibility (e.g. 
combination of different tracers to look at different biologi-
cal aspects) and a role of PET in more accurately measuring 
full-body pharmacodynamics.
Guided therapy
Many (particularly oncology) patients undergo PET/CT 
scans on a regular basis, especially within the context of 
response evaluation (e.g. every three cycles in case of 
immune therapy). Reduction in administered dose offers 
the possibility of more frequent treatment assessments, and 
consequently the possibility to identify non-responders at an 
earlier stage, thereby offering the opportunity to terminate 
non-effective treatment earlier, and potentially switch swiftly 
to another, more successful treatment. The lower dose also 
enables repeat scans using labelled monoclonal antibodies 
that are associated with a higher radiation dose due to the 
need for a longer lived radionuclide such as 89Zr and 90Y. In 
addition, the improved sensitivity will result in improved 
image quality of radionuclides with these low positron 
abundance radionuclides. Ïn addition, the lower adminis-
tered dose allows for a combination of multiple tracers in 
the same patient (molecular fingerprinting).
Furthermore, the improved sensitivity profile of the 
LAFOV PET scanner enables acquisitions at later time 
points, i.e. up to five additional half-lives of a radiotracer. 
This may be important for several applications, e.g. for anti-
body imaging (which are characterised by very slow kinet-
ics) [21].
Finally, the extended field of view will be convenient 
for assessing the biodistribution of novel radiotracers, as 
multiple organ axes are captured in a single scan and in com-
bination with the dynamic acquisition kinetic information 
can prove valuable for more precise prediction of therapeutic 
efficacy, as illustrated by the erlotinib example.
Organ axes
It has become increasingly apparent that many diseases and 
conditions, originally thought to be confined within a single 
organ, are much more complex and involve the interplay of 
that organ with other organs or systems [22]. As an example, 
the gut–brain axis is a feature in neuroscience. Bacteria in 
the gut could have profound effects on the brain, and might 
be tied to a whole family of disorders [23]. There is also 
evidence that gut microbiota and their metabolites interfere 
with the host’s immune and endocrine systems [24]. Here, 
LAFOV PET scanners could be helpful by dynamic imaging 
of the immune system to track and trace immune cells of 
the gut that interact with adjacent as well as distant organs 
and tissues.
The work of Per Borghammer and colleagues advocates a 
retrograde involvement of the brain in idiopathic Parkinson’s 
disease. A caudorostral gradient of dysfunction as shown by 
molecular imaging supports the hypothesis that a-synuclein 
pathology in Parkinson’s disease initially targets peripheral 
autonomic nerves and then spreads rostrally to the brain-
stem [22, 25, 26]. Imaging studies that enable combined 
assessment of brain and spinal cord will provide information 
on the molecular basis of neurodegenerative diseases that 
originate in the brain, but extend into the spinal cord and 
potentially lead to partial or complete paralysis. The spinal 
cord is involved in several neurological disorders and a more 
detailed assessment of its relationship with the brain may be 
useful not only in personalising treatment, but also in iden-
tifying treatment targets and quantifying disease progres-
sion. Examples include elucidation of the role of microglial 
activation in motor neuron disease using, for example,  [18F]
DPA-714 [27] and the pathophysiology of progression in 
multiple-sclerosis, hereditary spastic paraplegia and unex-
plained medical myelopathy.
There is also evidence that connects cardiovascular func-
tion, neurochemical asymmetries and depression [28]. The 
brain–heart axis is further implicated in post-stroke cardio-
vascular complications known as the stroke-heart syndrome, 
sudden cardiac death and the Takotsubo syndrome, amongst 
other neurocardiogenic syndromes. In the early 1990s, a 
dynamic  [15O]H2O PET brain study identified the central 
nervous pathways of angina pectoris, highlighting the inter-
play between the brain and the heart in such patients [29]. 
One other obvious example would be the emerging evidence 
of the role of acute myocardial infarction (MI) that triggers 
both local and systemic inflammatory responses. PET imag-
ing with  [11C]methionine specifically identifies an astrocyte 
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component, enabling further dissection of the heart-brain 
axis in post-MI inflammation [30]. Another recent  [18F]FDG 
PET/CT study has linked resting amygdalar activity with 
cardiovascular events, indicating a potential mechanism to 
predict risk of cardiovascular disease caused by stress [31]. 
Within the last decade, novel targeted therapies for multiple 
pathophysiological mechanisms have been identified [32].
Appropriate interpretation of changes in markers of 
kidney function is essential during treatment of both acute 
and chronic heart failure. Better understanding of the role 
of cardio-renal interactions in heart failure is essential with 
respect to symptom development, disease progression and 
prognosis. Using LAFOV PET scanners, organ interactions 
can be studied before and during therapy. Again, a better 
understanding of these interactions may lead to precision 
medicine for individual patients [33]. What is unique about 
the LAFOV PET scanners is the inclusion of all relevant 
organs in a single FOV, enabling novel approaches to study 
physiological or pathophysiological interactions between 
organs, including brain–heart-kidney-liver-gut interactions.
Infection and inflammation
Infection and inflammation imaging has significantly 
expanded over the years, with special focus on gathering 
evidence-based data for clinical indications and providing 
guidelines and diagnostic flowcharts in collaboration with 
clinical societies. The arrival of the LAFOV PET/CT sys-
tems will provide a further boost to this field. Using cur-
rent SAFOV PET/CT scanners, false-negative scans can be 
expected in patients with low-grade chronic infections, bac-
terial growth on biofilms at the joint prosthesis or vascular 
graft site, in small infectious foci, or in infections with a 
small number of bacterial colonies [34, 35]. The LAFOV 
PET/CT scanner may reduce this problem and may lead to 
an increase in diagnostic accuracy in patients with bacte-
raemia, endocarditis, vascular graft infections and fracture-
related infections.
As mentioned earlier, the increased sensitivity of LAFOV 
PET makes it possible to reduce the injected dose. This is 
especially important for the field of infection and inflam-
mation, as it opens up the possibility to use labelled mono-
clonal antibodies (so-called immunoPET) also for this indi-
cation. As immunoPET is based on radionuclides with a 
longer half-life (such as 89Zr), at present, it is used almost 
exclusively in oncological patients with a relatively short 
life expectancy. By reducing the injected dose, immunoPET 
will also become feasible in younger patients with inflam-
matory diseases.
Another important aspect is a possible shift from inva-
sive procedures to non-invasive molecular imaging. An 
example is the follow-up of children and young adults 
with an inflammatory bowel disease (Crohn’s disease 
or ulcerative colitis). Nowadays, follow-up is performed 
yearly using an invasive colonoscopy under sedation. 
With LAFOV PET, this may be performed non-invasively 
within a few minutes using either  [18F]FDG or (in the 
future) more specific tracers without the need for sedation.
A potential game changer in research and clinic
The intrinsic strength of PET imaging is its ability to track 
the position of single annihilation events with infinitesimal 
precise timing information (i.e., fraction of a nanosecond 
[36]. This means that, in practice, the (imaging) temporal 
resolution is limited only by the sensitivity of the scanner. 
A substantial increase in counted annihilation photons will 
make it possible to improve statistics and reconstruct much 
shorter frames with acceptable signal to noise ratio (SNR). 
For example, the feasibility of 100 ms duration frames 
was recently shown as part of a 3D animation produced 
by a team at University of California, Davis [37]. This 
sensitivity boost allows to literally follow the radiotracer 
molecules whilst they travel within the human body and, 
due to the extended FOV of the scanner, measure kinetics 
for a range of organs [38]. More than that, it has recently 
been shown that fast kinetic parameters such as K1 can be 
derived from only a couple of minutes of an early dynamic 
scan [39]. Dynamic PET becomes more practical, straight-
forward, simpler and more powerful than ever before, and 
with the use of appropriate kinetic models it will provide 
more accurate, precise and reliable quantification about 
the body ecosystem, which will be a game changer in both 
clinical practice and research [40].
Another key advantage is dose reduction. Beyond the 
obvious, but important benefit of imaging more radiosensi-
tive populations such as children and pregnant women at 
lower dose [41], imaging will enable wider use of 18F radi-
onuclides for scanning volunteers, potentially more than 
once, without the need for dosimetry approval [42], some-
thing which will definitely be the case for 11C-labelled 
tracers [43]. The improved access to people without any 
underlying conditions will create a fast-track route for 
protocol optimisation and clinical translation of new or 
even existing radiotracers within a wider range of clinical 
conditions.
Finally, as already mentioned, lower administered doses 
provide the possibility to perform PET scans with multiple 
tracers in the same patient [44]. As such, LAFOV PET 
offers exciting opportunities to image a wide variety of 
targeted functions at the same point in time, thereby pro-
viding more detailed insights into the biology of diseases 
at a whole-body level.
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Clinical and board support
The purchase of any camera, and certainly of such an 
expensive PET/CT system, requires approval by the hospi-
tal management. This was obtained by generating the usual 
business case and highlighting the benefits of LAFOV PET 
over standard systems, thereby focusing on the new possi-
bilities for both the clinic and medical research. Somewhat 
surprisingly, the application was supported by all hospital 
departments, not only those who traditionally are involved 
in PET (e.g. neurology, cardiology and oncology), but also 
from those who are not familiar with PET. This clearly 
illustrates that LAFOV PET already has raised interest 
amongst disciplines that have not been active in molecular 
imaging yet. Clearly, this interest (and concrete plans) has 
been a strong argument in obtaining approval from the 
hospital management.
Business/financial plan
Given the advantages, one question behind the installation 
and further widespread adaptation of LAFOV PET is its 
high costs that makes it unaffordable for several hospi-
tals even in high-income countries [45]. Thus, a realistic 
business plan could focus on the potential of a LAFOV 
PET/CT scanner for increased patient throughput. How-
ever, in order to achieve this increase, several prerequisites 
need to be met, including (1) allowing for only a moderate 
decrease in injected dose compared with that used on con-
ventional PET/CT scanners; (2) radiochemistry logistics 
being able to keep up with rapid successive injections; (3) 
patient facilities, such as preparation room, waiting room 
and changing rooms being available for a higher number 
of patients; and (4) additional personnel being available 
to aid with increased patient logistics. Interestingly, clini-
cal practice in radiology and nuclear medicine has shown 
that introduction of higher-sensitivity systems (e.g. digital 
PET replacing analogue PET, 3 T MRI replacing 1.5 T 
MRI) usually is invested more in better image quality 
than in faster scans [8, 46]. These considerations should 
be included in the business plan to avoid overly optimis-
tic expectations on the number of patients who can be 
scanned per day using a LAFOV PET/CT.
However, if these new opportunities are materialised in 
clinical practice, a substantial increase in the use of PET 
as a diagnostic and therapeutic guidance tool can be antici-
pated. Although, at present, it may be financially difficult 
for some centres to replace their conventional scanners 
with a longer one, it may be the natural direction once 
there is a demand for increased scanning capacity. Once 
this happens, it will be cheaper for one centre to increase 
its scanning capacity by replacing a conventional PET/
CT scanner with an extended FOV PET/CT scanner rather 
than by two or three conventional PET/CT scanners, as the 
first option will need less space and less refurbishment.
A longer-term business plan should consider a substantial 
expansion of PET usage in other patient populations (e.g. 
paediatric) as well as screening healthy individuals with 
higher risk of specific diseases. Furthermore, the advantages 
offered by dynamic PET acquisitions for quantification (i.e. 
essentially increasing specificity and accuracy of acquired 
signals) would make LAFOV PET an essential and com-
monly used tool for more comprehensive guidance of many 
additional therapies.
Infrastructure
General information regarding the required infrastructure 
for any PET/CT scanner or even a clinical PET centre is 
widely available, e.g. by the International Atomic Energy 
Agency (IAEA) Human Health Series [47]. A clinical PET 
centre should have several rooms including, but not limited 
to, a general reception area with waiting area, a prepara-
tion room for tracer administration, a “hot” uptake room 
where patients stay for a certain period of time after injec-
tion to allow for sufficient uptake in the body (e.g. 60 min 
for  [18F]FDG) and of course the PET/CT scanning room(s). 
In addition, a separate control room is required as well as 
rooms for auxiliary equipment and staff. A dedicated toilet 
for patients is required to prevent radioactive contamina-
tion of staff and visitors/personnel. Depending on the scope 
of the centre, a cyclotron and good manufacturing practice 
(GMP) laboratories for production and dispensing of activ-
ity may be required or, if activity is purchased, a simple 
hot-cell for storage and unpacking may be sufficient. The 
remainder of this section will focus on special considerations 
when installing a LAFOV PET/CT scanner, in particular the 
scanner room and its shielding, the IT infrastructure and the 
operating requirements.
Structural modifications of the scanner room and floor 
depend on the actual system to be installed, with LAFOV 
PET/CT potentially requiring modifications of rooms ini-
tially optimised for traditional PET/CT scanners. An impor-
tant advantage of LAFOV scanners with intermediate length 
such as the Siemens Biograph Quadra (106-cm-long FOV) 
is that, in principle, they can be installed within a room 
that was previously used for a traditional PET/CT scanner 
because of the similarity in footprint. However, care should 
be taken to ensure that the additional weight of the device 
does not exceed the structural limits of the floor and that 
the extended FOV still allows for optimal logistics in the 
space around the scanner. Placing the device at a slight 
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angle within the room can create additional space and allows 
access for maintenance.
The amount of shielding depends on the size of the room, 
the workload of the system and local regulations. Typically, 
2–3-mm lead is required from floor to ceiling to shield for 
CT radiation. This includes windows which need to be from 
lead glass. To shield for the 511 keV annihilation radiation, 
higher amounts of shielding may be required, which can eas-
ily exceed 10 mm of lead. If the extended PET/CT is used 
solely in combination with considerable lower injected doses 
than for traditional PET/CT systems, less shielding may be 
appropriate, thereby reducing the costs for the scanner room. 
However, this would significantly limit the range of appli-
cations and would especially prevent dynamic and delayed 
imaging studies where higher amounts of radioactivity are 
still needed.
As mentioned above, one of the key features of LAFOV 
PET/CT is the ability to obtain complete dynamic PET data, 
which can be reconstructed offline into datasets with high 
temporal resolution. However, this requires storage of the 
raw (list mode) data, which can quickly amount up to several 
terabytes per hour of scan time, depending on the character-
istics of the tracer used and the injected dose (as the amount 
of recorded data is proportional to the number of counts). 
Nevertheless, for scientific use and artificial intelligence (AI) 
applications, storage of these list mode data is essential. This 
vast amount of data poses significant challenges for almost 
any existing hospital infrastructure at present. Although 
centralised storage of data at hospital IT facilities would 
be preferred, this might not always be possible, because a 
dedicated communication architecture (several 10 Gbps net-
work lines) would be required to centralised storage media. 
Therefore, possibly an acceptable and cost-effective option 
that does not disrupt existing hospital IT systems is to imple-
ment a storage buffer in the equipment room (e.g. 1 Petabyte 
RAID array) that can rapidly transfer recently acquired data 
back and forth to the PET/CT reconstruction workstation, 
and additionally move older data overnight to centralised 
hospital storage facilities.
All scanners come with a site planning guide, which 
stipulate the conditions under which they should be used. 
In particular, cooling of the scanner requires attention, as 
digital PET detectors require a constant temperature in order 
to function reliably. Considering the large number of detec-
tors in the extended FOV, these scanners can require several 
times the amount of cooling that is needed for traditional 
scanners, which may require upgrades of the hospital cool-
ing system.
For kinetic modelling and quantification, a system to inva-
sively measure radiotracer concentrations in arterial blood 
over time will be essential, at least until robust non-invasive 
solutions for calculating the arterial input function have 
been developed. Depending on the length of the scanner, 
easy access to the radial artery may be limited. Online blood 
withdrawal systems should be carefully evaluated, especially 
since longer lines between artery and detector result in more 
dispersion of the measured blood curve.
Standard respiratory and cardiac gating systems as well as 
optical trackers for real-time motion detection that are com-
patible with longer scanners would be important additional 
tools for enabling quantification. Simple restraint systems 
for minimising bulk motion of the body extremities are also 
advisable.
Validation
Upon installation of any PET system, validation according to 
the National Electrical Manufacturers Association (NEMA) 
protocols should be performed to ensure reproducibility with 
other PET systems. Spatial resolution, scatter fraction, noise-
equivalent count rate, sensitivity and image quality should 
be performed according to NEMA NU 2–2012, whereas 
NEMA NU 2–2018 includes protocols for co-registration 
accuracy and time-of-flight resolution [48, 49].
NEMA determines spatial resolution as the full width at 
half maximum of the point-spread function, using a point 
source at several positions in the FOV, and reconstructing 
the data without attenuation and scatter corrections. Both 
NEMA protocols mentioned above contain details on the 
recommended point source, with the 2018 protocol stress-
ing that systems with smaller crystal size will benefit from 
using a 74 kBq 22Na over the 3.7 kBq  [18F]FDG point source 
specified in the 2012 protocol.
For scatter correction and subsequent determination 
of the noise-equivalent count rate, a phantom consisting 
of a 70-cm-long polyethylene cylinder, with a line source 
inserted, is used to acquire data for 12 h. A total of five 
70-cm-long polyethylene tubes with an inner diameter of 
1 mm are used to eventually determine the system’s sensitiv-
ity. Image quality is evaluated using the PET NEMA NU2 
image quality phantom positioned in the centre of the FOV. 
This phantom consists of six spheres, of which four are filled 
with radioactivity (spheres to background ratio = 8:1), and 
two are filled with non-radioactive water. These phantoms 
may need to be extended sufficiently for a more complete 
performance evaluation of LAFOV systems and formal 
adaptations of NEMA protocols will be helpful.
Co-registration accuracy is determined by calculating 
the 3D vector between CT and PET centroids, which are 
determined by measuring a vial containing radioactivity 
and contrast agent at six different positions. The NEMA 
NU 2–2018 protocol describes a new method to calculate 
time-of-flight resolution from scatter data used for the noise-
equivalent count rate [50]. Finally, to comply with the new 
European Association of Nuclear Medicine Research Ltd. 
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(EARL) guidelines, it is recommended to measure the 
system’s EARL performance according to standardised 
reconstructions.
A separate characterisation that needs to be considered 
is the background intrinsic radiation emitted by the 176Lute-
tium-based scintillators. Due to the large amount of crys-
tal material, this background radiation may pose a limit for 
Table 1  Opportunities and challenges of long axial field of view PET scanners
New opportunities Challenges
Improved image quality and high signal to noise
• Decrease population sampling size which will lead to faster transla-
tion of new/existing radiotracers
• No need for post-filtering
• Reconstruct images at smaller voxel size
• Measure/correct motion using PET data
• Increase specificity/sensitivity
• Increase reproducibility
• Detect low-grade uptake
• Detect disease at earlier stages
• Amend standardisation values/harmonisation
• Substantially non-uniform sensitivity along the axial field of view
Short imaging protocols
• High patient throughput
• Avoid anaesthesia in children
• Scan ICU patients
• Reduce motion artefacts
• Reduce patient inconvenience and consequently increase compliance
• Increase screening high-risk but otherwise healthy individuals
• More hot uptake rooms needed
Imaging with lower doses (as many more otherwise lost counts can be measured)
• Imaging radiosensitive populations (paediatrics, pregnant women)
• Imaging larger populations which will lead to faster translation of 
new/existing radiotracers and better understanding of health/disease
• Less affected by radiophobia, which will help replace other diagnos-
tic procedures
• Use radiotracers with poor labelling efficiency or low positron emis-
sion branching ratio
• Wider acceptance for use in clinical trials
• Imaging the same patient more sessions, which will lead to frequent/
accurate therapy evaluation
• Still requires CT for attenuation correction, which poses a significant 
limit to dose reduction (unless CT scan is avoided.)
• Intrinsic 176Lutetium radiation adds background noise
Imaging kinetics with greater temporal range
• Imaging slower biological processes (e.g. radionuclide therapy and 
immunotherapy)
• Imaging faster biological process due to higher temporal sampling
• Imaging biological processes for much longer half-lives of the radi-
otracer
• Derive accurate input function from short frames
• Extract more relevant/valuable information from one scan
• Increase specificity/sensitivity
• Increase reproducibility
• Identify input function delay in different organs
• Enabling imaging more than one tracer simultaneously
• Require accurate motion correction
• Require input function
• Require metabolites
• Require appropriate kinetic model due to kinetic heterogeneity
• Slow computational times for reconstruction, data corrections and 
kinetic modelling
Imaging longer axial FOV
• Imaging multiple regions at the body and investigate potential cor-
relations
• Biodistribution of newly developed (potentially radiolabelled) drugs
• Improve accuracy of dose estimation for radionuclide or other radi-
omolecular therapies
• Measure input function from aortas
• Requires checks of structural limits of the floor
• Expensive (when compared to conventional PET)
• May require bigger space
• Makes difficult to withdraw blood samples or other interventions 
during the scan
• Claustrophobic patients will be harder to scan
• Increases environmental footprint
• Adaptation of current QA procedures with longer phantoms which 
can be more difficult and time-consuming to handle
• Data storage and networking infrastructure
• If it replaces several conventional scanners or breaks, no other scan-
ners available
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low-dose scanning protocols. If substantial, it needs to be 
accounted for in image reconstructions as part of the back-
ground correction.
Challenges
To fully exploit the exciting opportunities of LAFOV PET/
CT scanners, several practical challenges need to be tackled. 
First, it is likely that the extent of the axial FOV will make it 
more difficult to scan patients with claustrophobia (despite 
the shorter acquisition time) and, as mentioned above, with-
drawing arterial and venous blood samples may also be more 
difficult, as both radial artery and antecubital vein will be 
less accessible. In addition, as already mentioned, storing 
and processing of the enormous datasets are a challenge for 
the IT infrastructure. Nevertheless, it is expected that these 
practical issues will be resolved in the near future.
Next to the practical issues, there are also some more 
basic challenges, especially when capitalising on the full 
power of LAFOV PET systems for deriving reliable kinetic 
information. The first challenge is related to any type of 
body movement, including that of body extremities, as 
well as respiration and cardiac contraction. Due to the fully 
3D nature of the PET acquisition, motion artefacts may be 
more pronounced in longer scanners than in conventional 
scanners. Systematic research efforts have not managed to 
sufficiently resolve this challenge in conventional PET scan-
ning and it remains a key bottleneck for quantification of 
dynamic (body) studies. However, the high SNR of LAFOV 
PET systems provides some confidence of mitigating this 
issue successfully [51].
The second challenge is related to the invasive procedure 
of measuring the arterial input function, which is an essen-
tial step in extracting kinetic information. The high SNR of 
LAFOV PET scanners, however, provides an opportunity 
to produce non-invasively an image-derived input function 
(IDIF), as in most cases both the heart and the aorta will be 
in the FOV. In addition, an important advantage of an IDIF 
is that it is not prone to dispersion, which has to be taken 
into account when measuring arterial concentrations using 
an (external) online sampling system. Moreover, it will even 
be possible to correct for differences in arrival times at the 
different organs (since apart from those organs, also their 
feeding arteries are within the FOV). Indeed, impressive 
dynamic data from the nearly 2-m-long PET scanner at the 
University of California, Davis, have indicated that the arte-
rial input function could be measured with sufficiently high 
rates immediately after radiotracer injection, thus provid-
ing a new potential for translating kinetic analysis in clini-
cal practice [37]. For some tracers, such as  [18F]FDG and 
 [15O]H2O, arterial whole blood concentrations are sufficient 
for determining the arterial input function. For most other 
tracers, however, the metabolite-corrected arterial plasma 
curve is needed as input function, which means that arterial 
samples are still required to determine the fraction of parent 
compound. The availability of many organs in the field of 
view (with different kinetics) provides a means to develop 
more comprehensive modelling methods (e.g. simultaneous 
fitting) that will encompass formation of labelled metabo-
lites non-invasively [52] thereby obviating the need for arte-
rial sampling altogether.
LAFOV PET provides a possibility to obtain kinetic data 
for all organs within the FOV, thereby making it possible 
to quantify the underlying molecular targets and interac-
tions. The third challenge for LAFOV PET is that it requires 
kinetic analyses of huge datasets (especially if performed 
at the voxel level) combined with the fact that the optimal 
pharmacokinetic model may be different for different organs. 
Furthermore, the fact that the sensitivity of the scanner may 
vary substantially along the FOV requires careful considera-
tion. To handle these complexities in routine clinical prac-
tice or even research, some form of automation seems to be 
mandatory. This may be achieved by using AI and organ seg-
mentation in combination with data-driven methods such as 
cluster and spectral analysis, ideally generating parametric 
images, i.e. quantitative images of a molecular parameter of 
interest rather than simple (and inaccurate) uptake images. 
Clearly, routine use of this option will also require a radical 
change in mentality in future clinical practice, i.e. favour-
ing longer but more accurate scans over shorter but cheaper 
uptake scans. This can only be achieved by careful research 
studies documenting the additional value of fully quanti-
tative scans, keeping in mind that in this era of precision 
medicine patients deserve the best approach.
Conclusion
In this contribution, several opportunities and challenges 
for LAFOV PET have been described. Clearly, this is an 
anthology in which the main issues have been highlighted. 
A consolidated overview of opportunities and challenges is 
provided in Table 1. What the nuclear medicine and molecu-
lar imaging community can expect from these new PET/CT 
scanners is the delivery of more comprehensive information 
to the clinicians for advancing diagnosis, therapy evaluation 
and clinical research.
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